Europe
Premark Pharma announced the completion of a licensing deal with Novartis Pharma AG, granting Premark exclusive worldwide rights to develop and commercialise PMP2207, an ophthalmic ointment formulation, as a potential treatment for blepharitis.
Admedus Ltd announces the publication of an independent study assessing the performance of CardioCel® in the prestigious peer-reviewed journal, The Annals of Thoracic Surgery.
The cash and stock deal will provide AbbVie with a pipeline boost in new therapeutic areas and will also decrease the company’s long-term reliance on its cash cow, Humira.
GENFIT announced the signing of a licensing and collaboration agreement with Terns Pharmaceuticals, a global biopharmaceutical company based in the U.S. and China with a focus on developing novel and combination therapies to treat liver disease.
MorphoSys AG announced that its Supervisory Board has appointed Jean-Paul Kress, M.D., as its new Chief Executive Officer.
New Diagnostic Test, CERT, Improves Risk Prediction Over Standard Laboratory Tests
Domain Therapeutics announces the appointment of world-renowned GPCR and drug discovery and development experts to its Scientific Advisory Board (SAB): Pr. Silvio Gutkind, Pr. Morley Hollenberg and Pr. Brigitte Kieffer.
Medtronic plc announced the commencement of two cash tender offers by its wholly-owned indirect subsidiaries, Medtronic, Inc., Medtronic Global Holdings S.C.A. and Covidien International Finance S.A. (“CIFSA” and, together with Medtronic, Inc.
Novel antibody labelling immunoassay technology for multiplex immune profiling addresses one of the fastest growing, billion-dollar life science market sectors
NOXXON Pharma N.V. announced that a leading international pharmaceutical company amongst the top-10 pharmaceutical companies by worldwide revenue[1] has signed an agreement with NOXXON for the purpose of evaluating NOX-A12 in a new indication, which will remain undisclosed for competitive reasons.
PRESS RELEASES